Risk factors of uncontrolled symptoms using the standard dose of second-generation H1 -antihistamines in chronic spontaneous urticaria children

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20190720005

Enrollment

192

Registered

2019-07-20

Start date

2018-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic spontaneous urticaria chronic spontaneous urticaria child second&#45

Interventions

who were diagnosed with chronic spontaneous urticaria and initially treated with the standard dose of second&#45

generation H1 &#45

antihistamine

Treatment

CSU patient

18 years&#44

The CSU patients&#44

aged 2 &#45

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: The CSU patients, who were diagnosed with chronic spontaneous urticaria and initially treated with the standard dose of second-generation H1 -antihistamine

Exclusion criteria

Exclusion criteria: The patients who had underlying diseases related to urticaria or angioedema such as maculopapular cutaneous mastocytosis, urticarial vasculitis, bradykinin-mediated angioedema or cryopyrin-associated periodic syndrome, and patients on immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
Uncontrolled symptoms 4 weeks Clinical assessment by physician	—

Secondary

Measure	Time frame
Treatment outcome until the patients can controlled symptoms Descriptive data	—

Countries

Thailand

Contacts

Public ContactVanlaya Koosakulchai

Division of Allergy and Immunology, Department of Pediatrics

windyfernny@gmail.com0831946808

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Risk factors of uncontrolled symptoms using the standard dose of second&#45;generation H1 &#45;antihistamines in chronic spontaneous urticaria children